Antiherpesvirus drugs: A promising spectrum of new drugs and drug targets

被引：125

作者：

Coen, DM ^{[1
]}

Schaffer, PA

机构：

[1] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA

[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA

[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02215 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 04期

关键词：

D O I：

10.1038/nrd1065

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In the absence of effective vaccines to control herpesvirus infections, nucleosidic antiviral drugs have been the mainstay of clinical treatment since their development in the late 1970s. However, given the drawbacks of these drugs, including the increasing emergence of drug-resistant clinical isolates, new strategies for treating herpesvirus infections are warranted. A range of promising new drugs with novel molecular targets has been developed, but will they cure latent infections?

引用

页码：278 / 288

页数：11

共 80 条

[1] The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus [J].

Akanitapichat, P ;

Bastow, KF .

ANTIVIRAL RESEARCH, 2002, 53 (02) :113-126

[2] SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2 [J].

Albin, R ;

Chase, R ;

Risano, C ;

Lieberman, M ;

Ferrari, E ;

Skelton, A ;

Buontempo, P ;

Cox, S ;

DeMartino, J ;

WrightMinogue, J ;

JirauLucca, G ;

Kelly, J ;

Afonso, A ;

Kwong, AD ;

Rozhon, EJ ;

OConnell, JF .

ANTIVIRAL RESEARCH, 1997, 35 (03) :139-146

[3] Activation of IκB kinase by herpes simplex virus type 1 -: A novel target for anti-herpetic therapy [J].

Amici, C ;

Belardo, G ;

Rossi, A ;

Santoro, MG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :28759-28766

[4]

AZAC RF, 1993, ANTIMICROB AGENTS CH, V37, P1945

[5] Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase - Importance of the P+5 position [J].

Baek, MC ;

Krosky, PM ;

He, ZW ;

Coen, DM .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (33) :29593-29599

[6] Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action [J].

Biron, KK ;

Harvey, RJ ;

Chamberlain, SC ;

Good, SS ;

Smith, AA ;

Davis, MG ;

Talarico, CL ;

Miller, WH ;

Ferris, R ;

Dornsife, RE ;

Stanat, SC ;

Drach, JC ;

Townsend, LB ;

Koszalka, GW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2365-2372

[7] Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis [J].

Boivin, G ;

Gilbert, C ;

Gaudreau, A ;

Greenfield, I ;

Sudlow, R ;

Roberts, NA .

JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (12) :1598-1602

[8] Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: Selection and characterization of mutant isolates [J].

Bonneau, AM ;

Kibler, P ;

White, P ;

Bousquet, C ;

Dansereau, N ;

Cordingley, MG .

JOURNAL OF VIROLOGY, 1996, 70 (02) :787-793

[9] Identification and characterization of a benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection [J].

Boulware, SL ;

Bronstein, JC ;

Nordby, EC ;

Weber, PC .

ANTIVIRAL RESEARCH, 2001, 51 (02) :111-125

[10]

BOYD FL, 1999, 218 AM CHEM SOC NAT

← 1 2 3 4 5 6 7 8 →